metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus pembrolizumab alone
	atezolizumab plus cometinib vs. pembrolizumab alone	1	152 [-583; 888] /10000 45/222 vs. 42/224	450 [-476; 1377] /10000 121/222 vs. 112/224	-